Glucocorticoid use in paediatric posterior fossa tumour surgery and the occurrence of postoperative speech impairmentAlder Hey Childrens NHS Fdn Trust, Dept Paediat Oncol, Liverpool, England..
Univ Glasgow, Queen Elizabeth Univ Hosp, Dept Neurol, Univ Ave, Glasgow G12 8QQ, Scotland..
St Olavs Hosp, Dept Pediat Hematol & Oncol, Postboks 3250, N-7006 Trondheim, Norway. Oslo Univ Hosp, Dept Neurosurg, Postboks 4950, N-0424 Oslo, Norway..
Linköping Univ, Crown Princess Victor Childrens Hosp, Dept Biomed & Clin Sci, Linköping, Sweden..
Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Silvia Childrens Hosp, Childhood Canc Ctr, Gothenburg, Queen, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Neurosurgery.
Semmelweis Univ, Dept Pediat 2, Tuzolto U 7-9, H-1094 Budapest, Hungary.;BAZ Cty Cent Hosp, Velkey Laszlo Childs Hlth Ctr, Szentpeter Kapu 72-76, H-3526 Miskolc, Hungary.;Univ Teaching Hosp, Szentpeter Kapu 72-76, H-3526 Miskolc, Hungary..
Semmelweis Univ, Dept Pediat 2, Tuzolto U 7-9, H-1094 Budapest, Hungary..
IRCCS, Bambino Gesu Childrens Hosp, Dept Neurosci, Neurosurg Unit, Rome, Italy..
Univ Hosp Tuebingen, Dept Neurosurg, Pediat Neurosurg, Hoppe Seyler Str 3, D-72076 Tubingen, Germany..
Princess Maxima Ctr Pediat Oncol, Heidelberglaan 25, NL-3584 CS Utrecht, Netherlands..
Princess Maxima Ctr Pediat Oncol, Heidelberglaan 25, NL-3584 CS Utrecht, Netherlands..
Charles Univ Prague, Fac Med 2, Dept Neurosurg, Prague, Czech Republic.;Motol Univ Hosp, Prague, Czech Republic..
Med Univ Vienna, Dept Pediat & Adolescent Med, Waehringer Guertel 18-20, A-1090 Vienna, Austria..
Univ Hosp, Dept Paediat & Adolescent Med, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen E, Denmark..
Univ Hosp, Dept Paediat & Adolescent Med, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen E, Denmark..
Univ Hosp, Dept Paediat & Adolescent Med, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen E, Denmark.;Univ Copenhagen, Inst Clin Med, Fac Med, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark..
Univ Hosp, Dept Neurosurg, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen E, Denmark.;Univ Copenhagen, Inst Clin Med, Fac Med, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark.;Aarhus Univ Hosp, Dept Neurosurg, Palle Juul Jensens Blvd 99, DK-8200 Aarhus, Denmark..
Univ Hosp, Dept Paediat & Adolescent Med, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen E, Denmark.;Univ Hosp, Dept Neuroanesthesiol, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen E, Denmark..
Univ Hosp, Dept Paediat & Adolescent Med, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen E, Denmark.;Univ Copenhagen, Inst Clin Med, Fac Med, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark..
Show others and affiliations
2025 (English)In: Child's Nervous System, ISSN 0256-7040, E-ISSN 1433-0350, Vol. 41, no 1, article id 231Article in journal (Refereed) Published
Abstract [en]
Purpose
Postoperative speech impairment (POSI) is a core symptom of cerebellar mutism syndrome (CMS) and is a common complication after the resection of paediatric posterior fossa (PF) tumours. Preoperative glucocorticoids (pGC) are considered standard treatment to reduce tumour oedema; in addition, glucocorticoids are often administered intraoperatively (iGC) to reduce both postoperative nausea and vomiting. The study aims to investigate whether the occurrence of POSI may be associated with pGC and iGC.
Methods
In a prospective observational multicentre study, we included children with a PF tumour requiring either resection or open biopsy. The use of pGC and iGC, including drug type and dose, was registered. Postoperative speech status was classified as mutism, reduced speech, or habitual speech, where mutism and reduced speech were considered POSI of higher and lower severity, respectively. Proportional odds logistic regression with adjustment for tumour type, tumour location, and age was used to analyse the occurrence of POSI associated with glucocorticoids (GC).
Results
From August 2014 to November 2024, we recruited 810 children, of whom 605 were included in the primary analysis. We found no association between the use of GC (pGC nor iGC) and the occurrence of POSI. The result did not change when adjusting for tumour type, tumour location, and age. The analysis included both a comparison between using and not using pGC (OR 1.06 [95% CI 0.46 -2.49], reference level: use of pGC) and/or iGC (1.28 [0.58-2.82], reference level: use of iGC), and a dose-response analysis of the occurrence of POSI in relation to doubling the dose of GC (pGC OR 1.28 [0.84-1.98]; iGC OR 1.07 [0.62-1.82]).
Conclusion
Our study did not find evidence of a significant change in the occurrence of POSI with the use of pGC or iGC, but our results alone cannot rule out that the administration of pGC or iGC may have some effect. Therefore, our data do not call for a change in recommendations for the use of GC as protection against the development of POSI.
Trial registration number: Clinicaltrials.gov (NCT02300766).
Date of registration: November 25, 2014
Place, publisher, year, edition, pages
Springer, 2025. Vol. 41, no 1, article id 231
Keywords [en]
Cerebellar mutism syndrome, Neurosurgery, Brain neoplasm, Preoperative, Intraoperative, Postoperative speech impairment
National Category
Pediatrics Neurology
Identifiers
URN: urn:nbn:se:uu:diva-564397DOI: 10.1007/s00381-025-06850-0ISI: 001527743200001PubMedID: 40643729Scopus ID: 2-s2.0-105010445312OAI: oai:DiVA.org:uu-564397DiVA, id: diva2:1986857
2025-08-042025-08-042025-08-04Bibliographically approved